ANRO · Company research
Alto Neuroscience Inc. (ANRO): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
20records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold (NYSE:ANRO) - Seeking Alpha | Alto Neuroscience: Doubts Around Depression Candidate Merit Downgrade To Hold (NYSE:ANRO) Seeking Alpha | View source ↗ | Seeking Alpha | Oct 15, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Add ANRO Stock to Your Portfolio Now - Zacks Investment Research | Here's Why You Should Add ANRO Stock to Your Portfolio Now Zacks Investment Research | View source ↗ | Zacks Investment Research | Oct 14, 2026 | neutral | 0 | 0.6 |
| Here's Why You Should Add ANRO Stock to Your Portfolio Now | Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Add ANRO Stock to Your Portfolio Now | Alto Neuroscience (ANRO), a clinical-stage biopharmaceutical company, is advancing its precision psychiatry pipeline with three key candidates. ALTO-207 for treatment-resistant depression showed encouraging phase IIa results, with phase IIb results expected in H2 2027. ALTO-300 and ALTO-100 are in phase IIb studies with top-line results expected in H1 2027 and mid-2027 respectively. ALTO-101 for schizophrenia-related cognitive impairment failed its primary endpoint but showed some secondary signals. Year-to-date, ANRO shares have risen 24.1%, outperforming the biotech industry's 2.9% growth. | View source ↗ | Zacks Investment Research | Oct 14, 2026 | bullish | 0.25 | 1 |
| Here's Why You Should Add ANRO Stock to Your Portfolio Now - Yahoo Finance | Here's Why You Should Add ANRO Stock to Your Portfolio Now Yahoo Finance | View source ↗ | Yahoo Finance | Oct 14, 2026 | neutral | 0 | 0.6 |
| Alto Neuroscience Inc. Stock Grades | ANRO - Barron's | Alto Neuroscience Inc. Stock Grades | ANRO Barron's | View source ↗ | Barron's | Oct 9, 2026 | neutral | 0 | 0.6 |
| ANRO Nov 2026 35.000 call (ANRO261120C00035000) Stock Price, News, Quote & History - Yahoo! Finance Canada | ANRO Nov 2026 35.000 call (ANRO261120C00035000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| Precision Trading with ANRO Group (ANRO) Risk Zones - Stock Traders Daily | Precision Trading with ANRO Group (ANRO) Risk Zones Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 7, 2026 | neutral | 0 | 0.6 |
| Precision Trading with ANRO Group (ANRO) Risk Zones - Stock Traders Daily | Precision Trading with ANRO Group (ANRO) Risk Zones Stock Traders Daily | View source ↗ | Stock Traders Daily | Oct 7, 2026 | neutral | 0 | 0.6 |
| At $2.32 a share, Alto Neuroscience (ANRO) CFO exercises options for 55,000 shares. - Stock Titan | At $2.32 a share, Alto Neuroscience (ANRO) CFO exercises options for 55,000 shares. Stock Titan | View source ↗ | Stock Titan | Oct 5, 2026 | neutral | 0 | 0.6 |
| Exercising options at $2.35, Alto Neuroscience (ANRO)'s CFO sells shares. - Stock Titan | Exercising options at $2.35, Alto Neuroscience (ANRO)'s CFO sells shares. Stock Titan | View source ↗ | Stock Titan | Oct 2, 2026 | neutral | 0 | 0.6 |
| Stock options underpin an officer's proposed share sale at Alto Neuroscience (NYSE: ANRO). - Stock Titan | Stock options underpin an officer's proposed share sale at Alto Neuroscience (NYSE: ANRO). Stock Titan | View source ↗ | Stock Titan | Sep 29, 2026 | neutral | 0 | 0.6 |
| (ANRO) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily | (ANRO) Price Dynamics and Execution-Aware Positioning Stock Traders Daily | View source ↗ | Stock Traders Daily | Aug 27, 2026 | neutral | 0 | 0.6 |
| Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? - Yahoo Finance | Alto Neuroscience (ANRO) Reports Another Quarterly Loss, Is The Stock Already Overvalued? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 16, 2026 | neutral | 0 | 0.6 |
| Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans - Yahoo Finance | Alto Neuroscience (ANRO) Stock Looks Stretched On Expanded ALTO 207 Plans Yahoo Finance | View source ↗ | Yahoo Finance | Aug 15, 2026 | neutral | 0 | 0.6 |
| Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding - Simply Wall Street | Why Alto Neuroscience (ANRO) Is Up 13.5% After Expanding ALTO-207 Phase 3 And Securing New Funding Simply Wall Street | View source ↗ | Simply Wall Street | Aug 14, 2026 | neutral | 0 | 0.6 |
| Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO) - Seeking Alpha | Alto Neuroscience: Buy ALTO-207 Advancement TRD And Other Expansion Indications (ANRO) Seeking Alpha | View source ↗ | Seeking Alpha | Aug 3, 2026 | neutral | 0 | 0.6 |
| ANRO - Alto Neuroscience Inc Stock Price and Quote - Finviz | ANRO - Alto Neuroscience Inc Stock Price and Quote Finviz | View source ↗ | Finviz | May 27, 2026 | neutral | 0 | 0.6 |
| ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point - Stocktwits | ANRO Stock Drops 7% After Disappointing Schizophrenia Study Results – But Analyst Sees Dip As Attractive Entry Point Stocktwits | View source ↗ | Stocktwits | Apr 2, 2026 | neutral | 0 | 0.6 |
| ANRO Stock Falls After Hours On Failed Schizophrenia Study Results - Stocktwits | ANRO Stock Falls After Hours On Failed Schizophrenia Study Results Stocktwits | View source ↗ | Stocktwits | Apr 1, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.